Sfoglia per Autore
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
2017-01-01 Bonelli, Mara; Digiacomo, Graziana; Fumarola, Claudia; Alfieri, Roberta; Quaini, Federico; Falco, Angela; Madeddu, Denise; LA MONICA, Silvia; Cretella, Daniele; Ravelli, Andrea; Ulivi, P; Tebaldi, M; Calistri, D; Delmonte, A; Ampollini, Luca; Carbognani, Paolo; Tiseo, Marcello; Cavazzoni, Andrea; Petronini, Pier Giorgio
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
2017-01-01 La Monica, Silvia; Cretella, Daniele; Bonelli, Mara; Fumarola, Claudia; Cavazzoni, Andrea; Digiacomo, Graziana; Flammini, Lisa; Barocelli, Elisabetta; Minari, Roberta; Naldi, Nadia; Petronini, Pier Giorgio; Tiseo, Marcello; Alfieri, Roberta
New therapeutic strategies for malignant pleural mesothelioma
2017-01-01 Bonelli, Mara; Fumarola, Claudia; LA MONICA, Silvia; Alfieri, Roberta
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
2017-01-01 Cavazzoni, Andrea; La Monica, Silvia; Alfieri, Roberta; Ravelli, Andrea; Steen, Nele Van Der; Sciarrillo, Rocco; Madeddu, Denise; Lagrasta, Costanza Anna Maria; Quaini, Federico; Bonelli, Mara; Fumarola, Claudia; Cretella, Daniele; Digiacomo, Graziana; Tiseo, Marcello; Peters, Godefridus J.; Ardizzoni, Andrea; Petronini, Pier Giorgio; and Elisa, Giovannetti
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment
2018-01-01 Cavazzoni, A.; Digiacomo, G.; La Monica, S.; Alfieri, R.; Fiorentino, M.; Ardizzoni, A.; Petronini, Pg.
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT
2018-01-01 Madeddu, Denise; Falco, A.; Cretella, D.; La Monica, S.; Lorusso, B.; Frati, C.; Lagrasta, C.; Cavalli, S.; Alfieri, R.; Mazzaschi, G.; Armani, G.; Gnetti, L.; Bonomini, S.; Bocchialini, G.; Rusca, M.; Quaini, F.; Ampollini, L.
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
2018-01-01 Cretella, Daniele; Ravelli, Andrea; Fumarola, Claudia; LA MONICA, Silvia; Digiacomo, Graziana; Cavazzoni, Andrea; Alfieri, Roberta; Biondi, Alessandra; Generali, Daniele; Bonelli, Mara; Petronini, Pier Giorgio
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models
2018-01-01 Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
2018-01-01 Minari, Roberta; Bordi, Paola; La Monica, Silvia; Squadrilli, Anna; Leonetti, Alessandro; Bottarelli, Lorena; Azzoni, Cinzia; Lagrasta, Costanza Anna Maria; Gnetti, Letizia; Campanini, Nicoletta; Petronini, Pier Giorgio; Alfieri, Roberta; Tiseo, Marcello
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models
2018-01-01 Morgillo, F.; Corte, C. M. Della; Alfieri, R.; Petronini, P.; La Monica, S.; Papaccio, F.; Ciardiello, F.
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells
2018-01-01 Digiacomo, Graziana; Fumarola, Claudia; Cretella, Daniele; Alfieri, Roberta; LA MONICA, Silvia; Petronini, Pier Giorgio; Bonelli, Mara; Cavazzoni, Andrea
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms
2019-01-01 Cretella, D; La Monica, S; Minari, R; Cavazzoni, A; Galetti, M; Petronini, P. G.; Tiseo, M; Alfieri, R.
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
2019-01-01 Fumarola, C; Bozza, N; Castelli, R; Ferlenghi, F; Marseglia, Giuseppe; Lodola, A; Bonelli, M; La Monica, S; Cretella, D; Alfieri, R; Minari, R; Galetti, M; Tiseo, M; Ardizzoni, A; Mor, M; Petronini, Pg.
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
2019-01-01 Rihawi, K; Alfieri, R; Fiorentino, M; Fontana, F; Capizzi, E; Cavazzoni, A; Terracciano, M; La Monica, S; Ferrarini, A; Buson, G; Petronini, Pg; Ardizzoni, A
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
2019-01-01 Cretella, D.; Fumarola, C.; Bonelli, M.; Alfieri, R.; La Monica, S.; Digiacomo, G.; Cavazzoni, A.; Galetti, M.; Generali, D.; Petronini, P. G.
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
2019-01-01 La Monica, S.; Minari, R.; Cretella, D.; Flammini, L.; Fumarola, C.; Bonelli, M.; Cavazzoni, A.; Digiacomo, G.; Galetti, M.; Madeddu, D.; Falco, A.; Lagrasta, C. A.; Squadrilli, A.; Barocelli, E.; Romanel, A.; Quaini, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R.
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
2019-01-01 Bonelli, M.; La Monica, S.; Fumarola, C.; Alfieri, R.
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion
2019-01-01 La Monica, S.; Minari, R.; Cretella, D.; Bonelli, M.; Fumarola, C.; Cavazzoni, A.; Galetti, M.; Digiacomo, G.; Riccardi, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R.
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells
2020-01-01 Bonelli, M.; Terenziani, R.; Zoppi, S.; Fumarola, C.; La Monica, S.; Cretella, D.; Alfieri, R.; Cavazzoni, A.; Digiacomo, G.; Galetti, M.; Petronini, P. G.
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer
2020-01-01 Cavazzoni, A.; Digiacomo, G.; Alfieri, R.; La Monica, S.; Fumarola, C.; Galetti, M.; Bonelli, M.; Cretella, D.; Barili, V.; Zecca, A.; Giovannetti, E.; Fiorentino, M.; Tiseo, M.; Petronini, P. G.; Ardizzoni, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. | 1-gen-2017 | Bonelli, Mara; Digiacomo, Graziana; Fumarola, Claudia; Alfieri, Roberta; Quaini, Federico; Falco, Angela; Madeddu, Denise; LA MONICA, Silvia; Cretella, Daniele; Ravelli, Andrea; Ulivi, P; Tebaldi, M; Calistri, D; Delmonte, A; Ampollini, Luca; Carbognani, Paolo; Tiseo, Marcello; Cavazzoni, Andrea; Petronini, Pier Giorgio | |
| Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines | 1-gen-2017 | La Monica, Silvia; Cretella, Daniele; Bonelli, Mara; Fumarola, Claudia; Cavazzoni, Andrea; Digiacomo, Graziana; Flammini, Lisa; Barocelli, Elisabetta; Minari, Roberta; Naldi, Nadia; Petronini, Pier Giorgio; Tiseo, Marcello; Alfieri, Roberta | |
| New therapeutic strategies for malignant pleural mesothelioma | 1-gen-2017 | Bonelli, Mara; Fumarola, Claudia; LA MONICA, Silvia; Alfieri, Roberta | |
| Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN | 1-gen-2017 | Cavazzoni, Andrea; La Monica, Silvia; Alfieri, Roberta; Ravelli, Andrea; Steen, Nele Van Der; Sciarrillo, Rocco; Madeddu, Denise; Lagrasta, Costanza Anna Maria; Quaini, Federico; Bonelli, Mara; Fumarola, Claudia; Cretella, Daniele; Digiacomo, Graziana; Tiseo, Marcello; Peters, Godefridus J.; Ardizzoni, Andrea; Petronini, Pier Giorgio; and Elisa, Giovannetti | |
| PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment | 1-gen-2018 | Cavazzoni, A.; Digiacomo, G.; La Monica, S.; Alfieri, R.; Fiorentino, M.; Ardizzoni, A.; Petronini, Pg. | |
| MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT | 1-gen-2018 | Madeddu, Denise; Falco, A.; Cretella, D.; La Monica, S.; Lorusso, B.; Frati, C.; Lagrasta, C.; Cavalli, S.; Alfieri, R.; Mazzaschi, G.; Armani, G.; Gnetti, L.; Bonomini, S.; Bocchialini, G.; Rusca, M.; Quaini, F.; Ampollini, L. | |
| The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells | 1-gen-2018 | Cretella, Daniele; Ravelli, Andrea; Fumarola, Claudia; LA MONICA, Silvia; Digiacomo, Graziana; Cavazzoni, Andrea; Alfieri, Roberta; Biondi, Alessandra; Generali, Daniele; Bonelli, Mara; Petronini, Pier Giorgio | |
| Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models | 1-gen-2018 | Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana | |
| Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC | 1-gen-2018 | Minari, Roberta; Bordi, Paola; La Monica, Silvia; Squadrilli, Anna; Leonetti, Alessandro; Bottarelli, Lorena; Azzoni, Cinzia; Lagrasta, Costanza Anna Maria; Gnetti, Letizia; Campanini, Nicoletta; Petronini, Pier Giorgio; Alfieri, Roberta; Tiseo, Marcello | |
| 155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models | 1-gen-2018 | Morgillo, F.; Corte, C. M. Della; Alfieri, R.; Petronini, P.; La Monica, S.; Papaccio, F.; Ciardiello, F. | |
| Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells | 1-gen-2018 | Digiacomo, Graziana; Fumarola, Claudia; Cretella, Daniele; Alfieri, Roberta; LA MONICA, Silvia; Petronini, Pier Giorgio; Bonelli, Mara; Cavazzoni, Andrea | |
| CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms | 1-gen-2019 | Cretella, D; La Monica, S; Minari, R; Cavazzoni, A; Galetti, M; Petronini, P. G.; Tiseo, M; Alfieri, R. | |
| Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. | 1-gen-2019 | Fumarola, C; Bozza, N; Castelli, R; Ferlenghi, F; Marseglia, Giuseppe; Lodola, A; Bonelli, M; La Monica, S; Cretella, D; Alfieri, R; Minari, R; Galetti, M; Tiseo, M; Ardizzoni, A; Mor, M; Petronini, Pg. | |
| MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report | 1-gen-2019 | Rihawi, K; Alfieri, R; Fiorentino, M; Fontana, F; Capizzi, E; Cavazzoni, A; Terracciano, M; La Monica, S; Ferrarini, A; Buson, G; Petronini, Pg; Ardizzoni, A | |
| Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells | 1-gen-2019 | Cretella, D.; Fumarola, C.; Bonelli, M.; Alfieri, R.; La Monica, S.; Digiacomo, G.; Cavazzoni, A.; Galetti, M.; Generali, D.; Petronini, P. G. | |
| Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC | 1-gen-2019 | La Monica, S.; Minari, R.; Cretella, D.; Flammini, L.; Fumarola, C.; Bonelli, M.; Cavazzoni, A.; Digiacomo, G.; Galetti, M.; Madeddu, D.; Falco, A.; Lagrasta, C. A.; Squadrilli, A.; Barocelli, E.; Romanel, A.; Quaini, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R. | |
| Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation | 1-gen-2019 | Bonelli, M.; La Monica, S.; Fumarola, C.; Alfieri, R. | |
| Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion | 1-gen-2019 | La Monica, S.; Minari, R.; Cretella, D.; Bonelli, M.; Fumarola, C.; Cavazzoni, A.; Galetti, M.; Digiacomo, G.; Riccardi, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R. | |
| Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells | 1-gen-2020 | Bonelli, M.; Terenziani, R.; Zoppi, S.; Fumarola, C.; La Monica, S.; Cretella, D.; Alfieri, R.; Cavazzoni, A.; Digiacomo, G.; Galetti, M.; Petronini, P. G. | |
| Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer | 1-gen-2020 | Cavazzoni, A.; Digiacomo, G.; Alfieri, R.; La Monica, S.; Fumarola, C.; Galetti, M.; Bonelli, M.; Cretella, D.; Barili, V.; Zecca, A.; Giovannetti, E.; Fiorentino, M.; Tiseo, M.; Petronini, P. G.; Ardizzoni, A. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile